CN102802635B - 麻醉药制剂 - Google Patents

麻醉药制剂 Download PDF

Info

Publication number
CN102802635B
CN102802635B CN201180013975.2A CN201180013975A CN102802635B CN 102802635 B CN102802635 B CN 102802635B CN 201180013975 A CN201180013975 A CN 201180013975A CN 102802635 B CN102802635 B CN 102802635B
Authority
CN
China
Prior art keywords
cyclodextrin
alfaxalone
anesthetic
rats
neuroactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180013975.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102802635A (zh
Inventor
朱丽叶·玛格丽特·古德柴尔德
科林·斯坦利·古德柴尔德
本杰明·詹姆斯·博伊德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suspension Bridge Pharmaceutical Co ltd
Original Assignee
Suspension Bridge Pharmaceutical Co ltd
Monash University
Goodchild Investments Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suspension Bridge Pharmaceutical Co ltd, Monash University, Goodchild Investments Pty Ltd filed Critical Suspension Bridge Pharmaceutical Co ltd
Publication of CN102802635A publication Critical patent/CN102802635A/zh
Application granted granted Critical
Publication of CN102802635B publication Critical patent/CN102802635B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180013975.2A 2010-01-21 2011-01-19 麻醉药制剂 Expired - Fee Related CN102802635B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US61/297,249 2010-01-21
US38531810P 2010-09-22 2010-09-22
US61/385,318 2010-09-22
PCT/AU2011/000050 WO2011088503A1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Publications (2)

Publication Number Publication Date
CN102802635A CN102802635A (zh) 2012-11-28
CN102802635B true CN102802635B (zh) 2014-07-30

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180013975.2A Expired - Fee Related CN102802635B (zh) 2010-01-21 2011-01-19 麻醉药制剂

Country Status (27)

Country Link
US (2) US8697678B2 (cg-RX-API-DMAC7.html)
EP (1) EP2525798B1 (cg-RX-API-DMAC7.html)
JP (1) JP5930311B2 (cg-RX-API-DMAC7.html)
KR (1) KR101747476B1 (cg-RX-API-DMAC7.html)
CN (1) CN102802635B (cg-RX-API-DMAC7.html)
AU (1) AU2011207103B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012017800B1 (cg-RX-API-DMAC7.html)
CA (1) CA2786762C (cg-RX-API-DMAC7.html)
CL (1) CL2012002032A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119947T1 (cg-RX-API-DMAC7.html)
DK (1) DK2525798T3 (cg-RX-API-DMAC7.html)
ES (1) ES2646829T3 (cg-RX-API-DMAC7.html)
GB (2) GB2491491B (cg-RX-API-DMAC7.html)
HR (1) HRP20171699T1 (cg-RX-API-DMAC7.html)
HU (1) HUE035441T2 (cg-RX-API-DMAC7.html)
LT (1) LT2525798T (cg-RX-API-DMAC7.html)
NO (1) NO2525798T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ601255A (cg-RX-API-DMAC7.html)
PL (1) PL2525798T3 (cg-RX-API-DMAC7.html)
PT (1) PT2525798T (cg-RX-API-DMAC7.html)
RS (1) RS56576B1 (cg-RX-API-DMAC7.html)
RU (1) RU2574022C2 (cg-RX-API-DMAC7.html)
SG (1) SG181997A1 (cg-RX-API-DMAC7.html)
SI (1) SI2525798T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700518T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011088503A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201205370B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
ES2784629T3 (es) 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
SG10201606063RA (en) * 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
RS62761B1 (sr) * 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
WO2014071449A1 (en) 2012-11-09 2014-05-15 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
US20150313915A1 (en) * 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
JP2018504420A (ja) * 2015-02-06 2018-02-15 マリナス ファーマシューティカルズ インコーポレイテッド 静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用
AR105044A1 (es) * 2015-06-18 2017-08-30 Sage Therapeutics Inc Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
US20170038184A1 (en) 2015-08-06 2017-02-09 Charles E. Ankner Formulation delivery system
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
KR20180082457A (ko) * 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019202640A1 (ja) 2018-04-16 2019-10-24 川崎重工業株式会社 ベルトコンベヤ
US11472833B2 (en) 2018-07-03 2022-10-18 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and methods of preparation
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
KR20210102936A (ko) * 2018-12-10 2021-08-20 헤일로 사이언스 엘엘씨 안정적인 마취제 제제 및 관련 복용량 형태
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
AU2020395254B2 (en) 2019-12-06 2026-04-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
CN115103591B (zh) 2019-12-27 2026-06-19 度勒科特公司 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399716A1 (en) * 1989-05-24 1990-11-28 Innovet, Inc. Hypoallergenic steroidal anesthetic/hypnotic compositions
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
WO2001070234A1 (en) * 2000-03-20 2001-09-27 Jurox Pty. Ltd. Anaesthetic composition
WO2004039426A3 (en) * 2002-10-31 2004-09-10 Transpharma Medical Ltd Transdermal delivery system for water insoluble drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
ES2812250T3 (es) * 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399716A1 (en) * 1989-05-24 1990-11-28 Innovet, Inc. Hypoallergenic steroidal anesthetic/hypnotic compositions
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
WO2001070234A1 (en) * 2000-03-20 2001-09-27 Jurox Pty. Ltd. Anaesthetic composition
WO2004039426A3 (en) * 2002-10-31 2004-09-10 Transpharma Medical Ltd Transdermal delivery system for water insoluble drugs

Also Published As

Publication number Publication date
AU2011207103A1 (en) 2012-07-26
HK1169031A1 (en) 2013-01-18
RU2574022C2 (ru) 2016-01-27
PL2525798T3 (pl) 2018-05-30
US8975245B2 (en) 2015-03-10
US20140066417A1 (en) 2014-03-06
HUE035441T2 (en) 2018-05-02
CY1119947T1 (el) 2018-12-12
BR112012017800A2 (en) 2018-07-10
DK2525798T3 (da) 2017-11-20
US8697678B2 (en) 2014-04-15
HRP20171699T1 (hr) 2018-01-26
SI2525798T1 (en) 2018-01-31
EP2525798A4 (en) 2014-02-19
GB2491491B (en) 2014-07-30
PT2525798T (pt) 2017-11-15
SMT201700518T1 (it) 2018-01-11
ES2646829T3 (es) 2017-12-18
GB2484244A (en) 2012-04-04
GB2484244B (en) 2012-10-31
LT2525798T (lt) 2018-01-10
NZ601255A (en) 2013-09-27
ZA201205370B (en) 2013-09-25
KR20120136347A (ko) 2012-12-18
BR112012017800B1 (pt) 2020-12-08
US20120316146A1 (en) 2012-12-13
RU2012134321A (ru) 2014-02-27
JP5930311B2 (ja) 2016-06-08
SG181997A1 (en) 2012-08-30
WO2011088503A1 (en) 2011-07-28
GB201201842D0 (en) 2012-03-21
CL2012002032A1 (es) 2012-12-21
EP2525798B1 (en) 2017-08-09
KR101747476B1 (ko) 2017-06-14
RS56576B1 (sr) 2018-02-28
NO2525798T3 (cg-RX-API-DMAC7.html) 2018-01-06
JP2013517299A (ja) 2013-05-16
GB2491491A (en) 2012-12-05
EP2525798A1 (en) 2012-11-28
CA2786762C (en) 2017-12-05
AU2011207103B2 (en) 2013-03-21
BR112012017800A8 (pt) 2018-08-14
CN102802635A (zh) 2012-11-28
CA2786762A1 (en) 2011-07-28
GB201210657D0 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
CN102802635A (zh) 麻醉药制剂
CN107261152B (zh) 包含环糊精和疏水性药物的可注射药物组合物的防腐方法
EP3556349B1 (en) Parenteral liquid preparation comprising carbamate compound
US8293749B2 (en) Injectable meclizine formulations and methods
AU2013200895B2 (en) Anaesthetic formulation
CA3046458C (en) Parenteral liquid preparation comprising carbamate compound
AU2014200491A1 (en) Anaesthetic formulation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: DIAOQIAO PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: GOODCHILD INVESTMENT PTY LTD.

Effective date: 20140319

Free format text: FORMER OWNER: MONASH UNIV.

Effective date: 20140319

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140319

Address after: Vitoria, Australia

Applicant after: Suspension Bridge Pharmaceutical Co.,Ltd.

Address before: Vitoria, Australia

Applicant before: GOODCHILD INVESTMENTS Pty Ltd.

Applicant before: MONASH University

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140730